Naslov: | Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity |
---|
Avtorji: | ID Vlačić, Gregor, Klinika Golnik (Avtor) ID Hoda, Mir Alireza (Avtor) ID Klikovits, Thomas (Avtor) ID Sinn, Katharina (Avtor) ID Gschwandtner, Elisabeth (Avtor) ID Mohorčič, Katja, Klinika Golnik (Avtor) ID Schelch, Karin (Avtor) ID Pirker, Christine (Avtor) ID Peter-Vörösmarty, Barbara (Avtor) ID Brankovic, Jelena (Avtor) ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Avtor) ID Rozman, Aleš, Klinika Golnik, Medicinska fakulteta UL (Avtor) ID Kern, Izidor, Klinika Golnik (Avtor) |
Datoteke: | PDF - Predstavitvena datoteka, prenos (1,74 MB) MD5: F0416A5D8E35B3782493059018061316
URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2073-4409/8/9/1091/pdf
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
---|
Povzetek: | Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute to MPM aggressiveness and it was suggested that subgroups of MPM patients could benefit from FGFR-targeted inhibitors. In the current investigation, we determined the expression of all four FGFRs (FGFR1-FGFR4) by immunohistochemistry in tissue samples from 94 MPM patients. From 13 of these patients, we were able to establish stable cell lines, which were subjected to FGFR1-4 staining, transcript analysis by quantitative RT-PCR, and treatment with the FGFR inhibitor infigratinib. While FGFR1 and FGFR2 were widely expressed in MPM tissue and cell lines, FGFR3 and FGFR4 showed more restricted expression. FGFR1 and FGFR2 showed no correlation with clinicopathologic data or patient survival, but presence of FGFR3 in 42% and of FGFR4 in 7% of patients correlated with shorter overall survival. Immunostaining in cell lines was more homogenous than in the corresponding tissue samples. Neither transcript nor protein expression of FGFR1-4 correlated with response to infigratinib treatment in MPM cell lines. We conclude that FGFR3 and FGFR4, but not FGFR1 or FGFR2, have prognostic significance in MPM and that FGFR expression is not suffcient to predict FGFR inhibitor response in MPM cell lines. |
---|
Ključne besede: | malignant pleural mesothelioma, fibroblast growth factor receptors, azbestos, immunotherapy, chemotherapy, genomic analysis, infigratinib |
---|
Status publikacije: | Objavljeno |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Kraj izida: | Švica |
---|
Založnik: | MDPI |
---|
Leto izida: | 2019 |
---|
Št. strani: | str. 1-14 |
---|
Številčenje: | Vol. 8, iss. 9 |
---|
PID: | 20.500.12556/DiRROS-12527 |
---|
UDK: | 616-006 |
---|
ISSN pri članku: | 2073-4409 |
---|
DOI: | 10.3390/cells8091091 |
---|
COBISS.SI-ID: | 2048535409 |
---|
Avtorske pravice: | © 2019 by the authors |
---|
Opomba: | Soavtorji iz Slovenije: Katja Mohorcic, Tanja Cufer, Ales Rozman, Izidor Kern;
Nasl. z nasl. zaslona;
Opis vira z dne 17. 9. 2019;
Št. prispevka: 1091;
|
---|
Datum objave v DiRROS: | 07.10.2020 |
---|
Število ogledov: | 12493 |
---|
Število prenosov: | 1202 |
---|
Metapodatki: | |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |